LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. cut its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 62.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 18,571 shares of the medical instruments supplier's stock after selling 31,233 shares during the period. D. E. Shaw & Co. Inc. owned about 0.08% of LeMaitre Vascular worth $1,711,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Barclays PLC grew its holdings in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the period. Albion Financial Group UT grew its holdings in shares of LeMaitre Vascular by 5.7% in the fourth quarter. Albion Financial Group UT now owns 3,796 shares of the medical instruments supplier's stock valued at $350,000 after purchasing an additional 204 shares during the period. SG Americas Securities LLC purchased a new stake in shares of LeMaitre Vascular in the fourth quarter valued at about $158,000. Linden Thomas Advisory Services LLC grew its holdings in shares of LeMaitre Vascular by 5.6% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 34,482 shares of the medical instruments supplier's stock valued at $3,177,000 after purchasing an additional 1,834 shares during the period. Finally, KBC Group NV grew its holdings in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 410 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on LMAT shares. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital increased their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.14.

LeMaitre Vascular Trading Up 2.9%

NASDAQ:LMAT traded up $2.28 during mid-day trading on Friday, hitting $81.40. The stock had a trading volume of 205,755 shares, compared to its average volume of 167,047. The stock has a 50-day simple moving average of $84.19 and a two-hundred day simple moving average of $92.47. The company has a market capitalization of $1.84 billion, a PE ratio of 44.48, a PEG ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm's revenue was up 12.0% compared to the same quarter last year. During the same period last year, the business earned $0.44 EPS. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's payout ratio is 40.40%.

Insider Activity

In other news, CEO George W. Lemaitre sold 76,868 shares of LeMaitre Vascular stock in a transaction on Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer now owns 1,796,783 shares of the company's stock, valued at $154,146,013.57. The trade was a 4.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 102,009 shares of company stock valued at $8,721,836 in the last ninety days. 9.50% of the stock is currently owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.